Patent application number | Description | Published |
20100074899 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 03-25-2010 |
20110020337 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 01-27-2011 |
20110091450 | METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 04-21-2011 |
20110311549 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 12-22-2011 |
20120282263 | COMPOSITIONS FOR INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION - The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation. | 11-08-2012 |
20130266559 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 10-10-2013 |
20140056873 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 02-27-2014 |
20140205598 | Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 07-24-2014 |
20140235691 | Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection - The present invention relates to stable, preservative- and antioxidant-free liquid formulations of phenylephrine and ketorolac for injection. | 08-21-2014 |
20150064176 | METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 03-05-2015 |
Patent application number | Description | Published |
20090274920 | Thermoformed Article Made From Bio-Based Biodegradable Polymer Composition - The present invention provides a biodegradable polymer composition useful for manufacturing biodegradable in which, the process comprising: (1) providing a renewable polymer and/or natural fiber having: (a) a T | 11-05-2009 |
20100187296 | DOUBLE WALL CONTAINER WITH INTERNAL SPACER - A container according to a preferred embodiment of the present invention provides an inner wall and an outer wall wrapped therearound so as to define a double-wall container construction. A plurality of spacer elements are interposed between the inner and the outer walls so as to maintain a minimum thickness of an air space defined therebetween. | 07-29-2010 |
20100200647 | EMBOSSED PAPERBOARD CUP HOLDER - A paperboard cup holder for use with a hot coffee cup, the cup being tapered as in the form of a cross section of a right circular cone of relatively small taper angle. Such cups are generally of paperboard or plastic and are often used in vending machines and fast food retail outlets for serving hot coffee. The holder is formed from a flat, generally arcuate unitary paperboard blank having a convex outer edge and a concave inner edge. The arcuate length of the blank is substantially the same as the mid circumference of the cup, and the ends of the blank are glued together to form an annular holder. The upper edge of the blank integrally carries a plurality of flaps which bend 180 degrees to as to lie parallel with the main portion of the blank. The inter and outer surfaces of the paperboard blank are embossed, including the flaps. When the holder is slid onto a cup, the flaps are sandwiched between the outer (hot) surface of the cup and the main portion of the holder. The flap apertures define small, closed air chambers which assist, with the paperboard of the holder, in inhibiting heat flow to the fingers of the person holding the cup. Spaces between the flaps and the surface embossing define air filled channels which further assist in inhibiting heat flow from the hot coffee to the finger tips of the user. | 08-12-2010 |
20110135863 | THERMOFORMED ARTICLES MADE FROM REACTIVE EXTRUSION PRODUCTS OF BIOBASED MATERIALS - The present invention is directed to a method of producing a themoformable composite by crosslinking PHA and PLA together in the presence of an additive to produce PHA and PLA blend and resins having: (a) a T | 06-09-2011 |
20110136978 | THERMOFORMED ARTICLE MADE FROM POLYBUTYLENE SUCCINATE (PBS) AND MODIFIED POLYBUTYLENE SUCCINATE (MPBS) - The present invention relates to articles made of a thermoformable resin comprising a biodegradable polymer having polybutylene succinate (PBS) via extrusion using an extruder which comprise: a biodegradable polymer having: (a) a T | 06-09-2011 |
20120097602 | BIODEGRADABLE OR COMPOSTABLE BEVERAGE FILTER CARTRIDGE - A biodegradable beverage filter cartridge having: a biodegradable fluid permeable beverage filter component; an openable lid component of biodegradable and/or recyclable material; and a beverage receptacle component composed of an exterior biodegradable heat-resistant structural polymer layer, an inner protective seal layer of biodegradable polymer, and an intermediate biodegradable and/or recyclable oxygen barrier layer between the exterior and inner layers and provided with a pierceable and/or a liquid permeable base portion and a sidewall portion extending generally upwardly from the base portion for securing the lid component to the beverage receptacle component and defining a beverage filter component receptacle area for receiving the beverage filter component. The cartridge may optionally include beverage material positioned within a beverage material receiving area of the beverage filter component. | 04-26-2012 |
20130001289 | PAPERBOARD CUP WITH MOISTURE ABSORBING PROTECTION - An open-top cup comprises a bottom wall and a side wall having inner and outer surfaces extending upwardly from the bottom wall. An outwardly curled lip formed on the free edge of the side wall. A respective insulative layer having a moisture absorbing characteristic and a respective graphic layer are attached to the outer surface of the side wall. The insulative layer is sandwiched between the outer surface of the side wall and the graphic layer. | 01-03-2013 |
20140091490 | PROCESS FOR MANUFACTURING ARTICLES COMPRISING POLYLACTIC ACID POLYMERS HAVING IMPROVED HEAT RESISTANCE - A process for thermoforming a discrete section of an amorphous pliable thermoplastic sheet in a temperature-controlled thermoforming mold to provide a discrete thermoformed section having one or more discrete shaped articles formed therein and to heat the shaped articles to a temperature below the T | 04-03-2014 |
Patent application number | Description | Published |
20100081619 | Peptide Toxin Formulation - Procedures are described which use solvents to increase the topical insecticidal activity of toxic insect peptides. These procedures comprise drying the peptides, if needed, followed by the addition of either: 1) a polar organic solvent, with or without water, to a dried peptide, or 2) the addition of polar aprotic solvent or other adjuvant to the dried peptide, followed by the addition of either: 1) a polar organic solvent, with or without water, (where a polar aprotic solvent is added first) or 2) a polar aprotic solvent or other adjuvant to the peptide polar organic solvent (where the polar organic solvent is added first), to the peptide formulation. | 04-01-2010 |
20130017992 | PEPTIDE TOXIN FORMULATION - Procedures are described which use solvents to increase the topical insecticidal activity of toxic insect peptides. These procedures comprise drying the peptides, if needed, followed by the addition of either: 1) a polar organic solvent, with or without water, to a dried peptide, or 2) the addition of polar aprotic solvent or other adjuvant to the dried peptide, followed by the addition of either: 1) a polar organic solvent, with or without water, (where a polar aprotic solvent is added first) or 2) a polar aprotic solvent or other adjuvant to the peptide polar organic solvent (where the polar organic solvent is added first), to the peptide formulation. | 01-17-2013 |
20130184434 | Peptide Toxin Formulation - Procedures are described which use solvents to increase the topical insecticidal activity of toxic insect peptides. These procedures comprise drying the peptides, if needed, followed by the addition of either: 1) a polar organic solvent, with or without water, to a dried peptide, or 2) the addition of polar aprotic solvent or other adjuvant to the dried peptide, followed by the addition of either: 1) a polar organic solvent, with or without water, (where a polar aprotic solvent is added first) or 2) a polar aprotic solvent or other adjuvant to the peptide polar organic solvent (where the polar organic solvent is added first), to the peptide formulation. | 07-18-2013 |